ArticleCureus2025
Stereotactic Radiosurgery for Patients With Five or More Brain Metastases: Retrospective Single-Institution Analysis of Prognostic Factors.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Review
- Article
- Article
- Spatially fractionated radiation therapy for treating recurrent glioblastoma: a dosimetric feasibility study.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe describe patient outcomes and prognostic factors following linear accelerator-based stereotactic radiosurgery (SRS) for five or more brain metastases, without prior or planned whole-brain radiotherapy.
methodsWe identified 116 eligible patients treated with SRS from 2019 to 2024 for newly diagnosed brain metastases. We describe clinical factors associated with survival ≤2 months and analyze brain metastasis velocity measured as the number (BMV) or volume (vBMV) of new metastases per year.
resultsThe number of treated brain metastases ranged from 5 to 41 (median 10); net lesion volume ranged from 0.1 to 59.8 (median 5.2) cc. Primary cancers included non-small cell lung (n=65), melanoma (n=20), breast (n=19), kidney (n=6), gastrointestinal (n=4), and other (n=4) cancers. The 6-, 12-, and 24-month overall survival (OS) was 60.3%, 40.5%, and 28.0%, respectively. A progressive extracranial disease at the time of brain metastases and lower predicted survival from graded prognostic assessments (GPAs) were significantly adverse factors for OS on multivariable Cox regression and were associated with 'poor survivors' who died ≤2 months from SRS (n=21) or at >2 months but opting against post-SRS cancer care and follow-up imaging (n=6; OS=2.1-5.8 months). Forty-two patients developed new brain metastases after SRS, while 28 (after ≥6-month follow-up) did not. Among these patients, OS was significantly associated with BMV and vBMV, though vBMV was not significant on multivariable Cox regressions that included BMV.
conclusionsFor patients with five or more brain metastases, clinical factors, including the status of extracranial disease and GPA, can potentially aid in selecting patients best-suited for SRS for multiple brain metastases, versus potentially deferring SRS in favor of supportive care. While vBMV is associated with OS, BMV appears more prognostic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.